Mannkind Corporation
$3.7M 10,087 recipients
Compare payment profiles
CMS Open Payments · Program Year 2024
Gramercy Extremity Orthopedics LLC
Gramercy Extremity Orthopedics LLC reported $3,662,286.94 across General Payments, Research, and Ownership to 106 physicians and teaching hospitals across 162 transactions.
- $3.7M
- All-tracks total
- 162
- Transactions
- 106
- Recipients
- −$29.4K
- General Payments vs PY2023
Gramercy Extremity Orthopedics LLC reported $3,662,286.94 across all CMS Open Payments tracks (General + Research + Ownership) to 106 physicians and teaching hospitals in Program Year 2024 - ranking #321 of 1,925 reporting manufacturers (0.0% of the all-tracks industry total); General Payments alone were $51,036.94, averaging $34.5K per recipient.
Data currency: Figures are rendered from the processed CMS Open Payments release. See our methodology for source dates and refresh cadence. Spot a figure that looks wrong? Report a correction.
CMS Sunshine Act warrant
Manufacturer gramercy-extremity-orthopedics-llc Gramercy Extremity Orthopedics LLC
$3.7M · #321/1,925 · 0.0% industry · PY2024
- TOT $3.7M
- RANK #321
- SHARE 0.0%
- TXN 162
- RCP 106
- CAT 3
- GEN $51.0K
- ΔGEN −$29.4K
- TOP1 11.3%
- PY 2024
Volume peers
Nearest volume peer: Mannkind Corporation ($3.7M)
Gramercy Extremity Orthopedics LLC sits among 1,925 manufacturers disclosing under the Physician Payments Sunshine Act. Volume peers below are nearest by all-tracks total, not corporate affiliates. Open the company rankings →
Release-over-release change
General Payments changed from PY2023 to PY2024
Gramercy Extremity Orthopedics LLC's CMS-reported General Payments decreased by $29.4K (−36.5%) from PY2023 to PY2024.
How this year-over-year comparison is scoped
The comparison uses consecutive CMS program years only (current = prior + 1) from the manufacturer General Payments summary and excludes research and ownership or investment records. Non-consecutive year pairs are not shown as year-over-year change. This General Payments figure is not the all-tracks company total in the hero.
CMS source labels for this exact identifier: PY2022: GRAMERCY EXTREMITY ORTHOPEDICS LLCPY2023: GRAMERCY EXTREMITY ORTHOPEDICS LLCPY2024: Gramercy Extremity Orthopedics LLC. Matching identifiers support a bounded record comparison; a label difference would be reported as unresolved rather than treated as a corporate event.
Subscribe to this company's source-bounded update feed It publishes only identifier-matched CMS release comparisons, never inferred company events.
General Payments: PY2023 vs PY2024
Annual CMS-reported totals for this company, not an all-category Open Payments total
- PY2023
- $80,430.52
- PY2024
- $51,036.94
What the Data Shows for Gramercy Extremity Orthopedics LLC
$3,662,286.94: that is what Gramercy Extremity Orthopedics LLC reported in payments to 106 physicians and teaching hospitals during Program Year 2024, spread across 162 transactions ($22.6K per transaction, $34.5K per recipient). The company sits at rank #321 of 1,925, a comparatively small 0.0% slice of all industry payments reported nationwide for the year.
"Consulting Fee" leads the 3-category general-payment breakdown below at $28.6K (56.1% of General Payments, 31 transactions) - see our methodology for how research and ownership payments are reported separately.
General Payment Breakdown by Type
Gramercy Extremity Orthopedics LLC made 3 types of general payments. "Consulting Fee" is the largest category at $28.6K, 56.1% of General Payments.
How Gramercy Extremity Orthopedics LLC divides its payments
General-payment categories, ordered by reported total
| Payment Type | Amount | Transactions | % of Total |
|---|---|---|---|
| Consulting Fee | $28.6K | 31 | 56.1% |
| Royalty or License | $21.1K | 62 | 41.3% |
| Food and Beverage | $1.3K | 13 | 2.6% |
Recipient Concentration in General Payments
The five largest recipient relationships account for $20,370.40 (39.9%) of $51,036.94 in this company's General Payments records across 29 recipients.
General Payments scope note
Program Year 2024 General Payments view only: excludes research and ownership/investment records, so it is not the all-category company total above.
Largest General-Payment relationships for Gramercy Extremity Orthopedics LLC
The five named recipients with the highest reported General Payments from this company
- 1
Matthew Lawrence
$5,775.00 across 7 reported transactions
- 2
Michal Szpara
$5,775.00 across 7 reported transactions
- 3
Shane Hollawell
$3,440.66 across 6 reported transactions
- 4
Gabriel Gambardella
$2,836.94 across 5 reported transactions
- 5
James Dejesus
$2,542.80 across 3 reported transactions
Compare this company's payment profile with similarly sized manufacturers in the company comparison tool, and consult the methodology for the CMS source scope.
Similarly Concentrated Companies
Companies whose General Payments are spread across recipients about as (un)evenly as Gramercy Extremity Orthopedics LLC's, measured by the same HHI concentration index above, not by payment size.
What HHI 2,500 means here
2,500 is the DOJ/FTC merger-guidelines threshold for "highly concentrated" markets; used here only as a familiar concentration reference, not a legal finding about Gramercy Extremity Orthopedics LLC.
Companies with Similar Payment Volumes
Open a profile or compare a similar company's CMS-reported payment pattern with Gramercy Extremity Orthopedics LLC.
Showing 6 of 1,924 companies with CMS-reported payment data.
Merz North America, Inc.
$3.6M 14,831 recipients
Compare payment profiles
Adcura, Inc.
$3.7M 0 recipients
Compare payment profiles
Paragon 28, Inc.
$3.7M 7,401 recipients
Compare payment profiles
Axonics, Inc.
$3.7M 21,250 recipients
Compare payment profiles
Haemonetics Corporation
$3.7M 1,963 recipients
Compare payment profiles
Data sourced from CMS Open Payments (Physician Payments Sunshine Act). See our methodology for details. Retrieved and formatted by PlainPharmaWatch
Disclaimer
This information is provided for informational purposes only and does not constitute professional advice. Data is sourced from the CMS Open Payments program. Consult a qualified professional before making decisions based on this data.
Read our methodology - how this data is sourced, computed, and verified.
Every figure on PlainPharmaWatch is rendered directly from federal source data, no number is typed in by an editor. This page draws directly on federal source data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of 2026-07-26.